Oppenheimer Analysts Give Verastem (VSTM) a $13.00 Price Target
Other research analysts have also recently issued research reports about the stock. Raymond James Financial reiterated a buy rating on shares of Verastem in a research note on Monday, December 11th. Cantor Fitzgerald set a $17.00 target price on shares of Verastem and gave the company a buy rating in a research note on Sunday, December 10th. Cann reiterated a buy rating and issued a $15.00 target price (up previously from $6.00) on shares of Verastem in a research note on Sunday, December 10th. HC Wainwright reiterated a buy rating and issued a $10.00 target price (up previously from $6.50) on shares of Verastem in a research note on Thursday, September 7th. Finally, Roth Capital started coverage on shares of Verastem in a research note on Friday, December 1st. They issued a buy rating and a $12.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $9.78.
Verastem (VSTM) opened at $2.99 on Thursday. The company has a market cap of $117.09, a PE ratio of -1.82 and a beta of 2.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.12 and a current ratio of 3.12. Verastem has a one year low of $1.08 and a one year high of $5.71.
Verastem (NASDAQ:VSTM) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.29). equities analysts expect that Verastem will post -1.74 EPS for the current year.
In related news, Director Timothy J. Barberich purchased 60,538 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average price of $3.95 per share, with a total value of $239,125.10. Following the completion of the acquisition, the director now directly owns 130,000 shares in the company, valued at approximately $513,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.51% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new stake in Verastem during the 3rd quarter worth $136,000. Northern Trust Corp grew its holdings in Verastem by 40.3% during the 2nd quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 21,178 shares during the period. Citadel Advisors LLC acquired a new stake in Verastem during the 3rd quarter worth $195,000. OxFORD Asset Management LLP acquired a new stake in Verastem during the 2nd quarter worth $234,000. Finally, Susquehanna International Group LLP grew its holdings in Verastem by 137.1% during the 3rd quarter. Susquehanna International Group LLP now owns 75,526 shares of the biopharmaceutical company’s stock worth $355,000 after acquiring an additional 43,675 shares during the period. 34.24% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/24/oppenheimer-analysts-give-verastem-vstm-a-13-00-price-target.html.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.